The biohacking aisle has become its own genre — NMN, NR, urolithin A, fisetin, spermidine, methylene blue, glycine-NAC. Each comes with a podcast clip, a mouse study, and a price tag that would have seemed insane a decade ago. The pitch is the same: optimize your mitochondria, extend your healthspan, cheat aging.
The science behind these compounds isn’t fraudulent. The leap from preliminary data to consumer product, however, is enormous, and that gap is where most of the money — and most of the disappointment — lives.
Mouse data is not human data
Mouse studies are useful for generating hypotheses. They are not useful for telling you what to take. Compounds like NMN and resveratrol produced impressive longevity signals in rodents and got mass-marketed before anyone had finished the human trials. When those trials arrived, results were modest, inconsistent, or null. Resveratrol — once positioned as the secret of red wine — failed to demonstrate the benefits its marketing claimed. NMN human trials so far have shown small biomarker shifts with unclear clinical relevance. Mice live two years and metabolize differently from humans. Translating the data faithfully takes a decade and often produces a humbler answer.
Bioavailability and dose are largely unsolved
Even when a compound has plausible activity, getting it into the right tissue at the right dose is a separate problem. Many biohacking favorites have poor oral bioavailability, meaning most of what you swallow never reaches the cells that supposedly benefit. Curcumin is the textbook example — extensively studied, biologically interesting, and barely absorbed without specialized formulations that the average consumer doesn’t buy. Brands solve this with proprietary delivery systems whose data they often don’t share. The result is a market full of pills doing far less than the studies they cite, even when those studies are real.
Real longevity gains come from less interesting interventions
Across every credible longevity database — the MIDUS study, the Blue Zones research, large-scale UK Biobank analyses — the interventions that actually move lifespan and healthspan are unfashionable. Not smoking, maintaining muscle mass, sleeping seven-plus hours, having strong social ties, treating hypertension and diabetes aggressively, getting recommended cancer screenings, staying physically active. None of those have a $90 monthly subscription. Compared to those, the marginal effect of any supplement stack is small enough to be lost in measurement noise. The longevity influencers’ personal regimens are often less informative than their basic blood pressure and VO2 max.
The bottom line
Biohacking supplements aren’t all snake oil. Some compounds may modestly help some people in some contexts, and rigorous human trials are ongoing. But the products on the shelf today are sold on extrapolation, not evidence. If you have the budget and curiosity to experiment, fine — keep doses reasonable, watch for side effects, and don’t stack ten things at once. Just don’t confuse the experiment with the strategy. The strategy is sleep, strength training, cardiovascular health, social connection, and seeing your doctor on schedule. That bundle is unsexy, and it’s the only one with the data to back the promise.
Leave a Reply